Journal
FUTURE MEDICINAL CHEMISTRY
Volume 6, Issue 2, Pages 179-204Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc.13.197
Keywords
-
Categories
Funding
- GlaxoSmithKline
- Pfizer-Neusentis
- UCB
- Biotechnology and Biological Sciences Research Council [1153133] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [986587, 1100658] Funding Source: researchfish
Ask authors/readers for more resources
Bromodomains are protein modules that bind to acetylated lysine residues and hence facilitate protein-protein interactions. These bromodomain-mediated interactions often play key roles in transcriptional regulation and their dysfunction is implicated in a large number of diseases. The discovery of potent and selective small-molecule bromodomain and extra C-terminal domain bromodomain ligands, which show promising results for the treatment of cancers and atherosclerosis, has promoted intense interest in this area. Here we describe the progress that has been made to date in the discovery of small-molecule bromodomain ligands, with particular emphasis on the roles played by phenotypic screening and fragment-based approaches. In considering the future of the field we discuss the prospects for development of molecular probes and drugs for the non-bromodomain and extra C-terminal domain bromodomains.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available